Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sitagliptin/simvastatin - Merck & Co

Next Previous
Search
Drug Profile

Sitagliptin/simvastatin - Merck & Co

Alternative Names: Januvia/Zocor; Juvicor; Juvisync; MK-0431D; MK-431D; Tesozor; Xelezor; Zocor/Januvia

Latest Information Update: 05 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck & Co
  • Class Antihyperglycaemics; Antihyperlipidaemics; Naphthalenes; Pyrazines; Small molecules; Triazoles
  • Mechanism of Action Dipeptidyl peptidase 4 inhibitors; HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Dyslipidaemias; Type 2 diabetes mellitus

Most Recent Events

  • 01 Aug 2017 Discontinued - Phase-III for Type-2 diabetes mellitus in Vietnam, Italy, Poland, Hungary, Latvia and Lithuania (PO), because not listed on Merck pipeline of August 2017
  • 30 Apr 2015 No recent reports on development identified - Phase-III for Type-2 diabetes mellitus in Vietnam (PO)
  • 01 Nov 2013 Merck terminates the phase III trial in Type-2 diabetes mellitus in USA, Lithuania, Latvia, Hungary, Poland and Italy for business reasons (EudraCT2012-001868-29; NCT01678820)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top